Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
Completed · Phase 1 · NCT02290951
Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
At a glance
- Research payments reported, 2025
- $377,960
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 200
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- Odronextamab multiple dose levels (drug), Odronextamab multiple dose levels (drug)
- Dates
- Started 2015-01-09; completion 2025-08-21
- Results posted
- Not yet
This study has two parts with distinct study objectives and study design. In part A, odronextamab is studied as an intravenous (IV) administration with a dose escalation and a dose expansion phase for B-NHL and CLL. The dose escalation phase for B-NHL and the CLL study are closed at the time of protocol amendment 17. In part B, odronextamab is studied as a subcutaneous (SC) administration with a dose finding and a dose expansion phase for B-NHL.
From ClinicalTrials.gov, last updated 2025-10-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $377,960 in research payments for this study in 2025 (17 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Susan M. O'brien, M.D. Medical Oncology · Orange, CA
- Stephen M. Ansell, M.D. Hematology · Rochester, MN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Uci Health - Fountain Valley, CA $293,694
- Mayo Clinic $52,315
- $31,951
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.